Climate Change Data

Beijing Tong Ren Tang Chinese Medicine Company Limited

Climate Impact & Sustainability Data (2023)

Reporting Period: 2023

Environmental Metrics

Total Carbon Emissions:2,005.3 tonnes CO2e/year
Scope 1 Emissions:115.6 tonnes CO2e/year
Scope 2 Emissions:1,798.7 tonnes CO2e/year
Scope 3 Emissions:91.0 tonnes CO2e/year
Renewable Energy Share:Not disclosed
Total Energy Consumption:4,525.7 MWh/year
Water Consumption:29,926.4 m3/year
Waste Generated:629.64 tonnes/year
Carbon Intensity:1.3 tonnes CO2e/HK$’ million of revenue

ESG Focus Areas

  • Product quality and safety
  • Responsible marketing and labeling
  • Protection of intellectual property rights
  • Occupational health and safety
  • Labor standards

Environmental Achievements

  • Reduced packaging material consumption by approximately 28.4% compared to the previous year.

Social Achievements

  • Held the "8th Show Love and Care to Stroke Prevention" event.
  • Provided free medical consultation services for more than 350 people.
  • Organized various community investment projects.

Governance Achievements

  • Maintained 100% anti-corruption training compliance for directors and senior management.
  • Established a "six-in-one" supervision system and a "one post with two responsibilities" mechanism.

Climate Goals & Targets

Long-term Goals:
  • Contribute to the globalization of the supply chain of raw materials of Chinese medicines and proprietary Chinese medicines.
Medium-term Goals:
  • Not disclosed
Short-term Goals:
  • Not disclosed

Environmental Challenges

  • Decrease in sales of Sporoderm-broken Ganoderma Lucidum Spores Powder in Mainland China due to post-pandemic market discrepancies and cautious consumer sentiment.
  • Global macroeconomic challenges including high interest rates and geopolitical tensions.
  • Cost pressures related to raw materials and manufacturing.
Mitigation Strategies
  • Implemented cost reduction and efficiency enhancement measures.
  • Maintained a steady supply of high-quality raw materials.
  • Actively explored new ways to modernize Chinese medicine services.
  • Expanded its markets worldwide.
  • Implemented a dual-driven strategy, including establishing new retail outlets and expanding international sales channels.

Supply Chain Management

Supplier Audits: 298 suppliers; selection process applicable to 94.9% of suppliers; environmental and social risk identification system and monitoring mechanism applicable to all suppliers; bi-yearly field audit and assessment for key materials suppliers.

Responsible Procurement
  • Materials testing to prohibit unqualified raw materials.
  • Supplier audits to ensure compliance with product quality standards.
  • Regular review of supplier performance and product quality.

Climate-Related Risks & Opportunities

Physical Risks
  • Increased frequency of typhoons and rainstorms
Transition Risks
  • Not disclosed
Opportunities
  • Not disclosed

Reporting Standards

Frameworks Used: Null

Certifications: Hong Kong Chinese patent medicine GMP, ISO22000, HACCP

Third-party Assurance: Not disclosed

UN Sustainable Development Goals

  • Not disclosed

Not disclosed

Sustainable Products & Innovation

  • Not disclosed

Awards & Recognition

  • Quam IR Awards 2022 – Sustainable Development Category – Gold